Sucralfate
Sucralfate, sold under various brand names, is a medication used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers. Its usefulness in people infected by H. pylori is limited. It is used by mouth (for upper GIT ulcers) and rectally (for radiation proctitis).
Clinical data | |
---|---|
Trade names | Carafate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a681049 |
License data |
|
Routes of administration | By mouth, rectal |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 3-5% (local acting) |
Metabolism | GI; liver: unknown |
Elimination half-life | unknown |
Excretion | Feces, urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.636 |
Chemical and physical data | |
Formula | C12H54Al16O75S8 |
Molar mass | 2086.67 g·mol−1 |
(what is this?) (verify) |
Common side effects include constipation. Serious side effects may include bezoar formation and encephalopathy. Use appears to be safe in pregnancy and breastfeeding. How it works is unclear but is believed to involve binding to the ulcer and protecting it from further damage.
Sucralfate was approved for medical use in the United States in 1981. It is available as a generic medication. In 2020, it was the 182nd most commonly prescribed medication in the United States, with more than 2 million prescriptions.